Overview

* Artelo Biosciences ( ARTL ) reports Q3 net loss of $3.1 mln, increased R&D and G&A expenses

* Positive interim Phase 2 data for ART27.13 attracts partnering interest

* Company completed public offering of common stock for $3.0 mln

Outlook

* Company expects first-in-human study for ART12.11 to start in 1H 2026

* Artelo sees partnering interest for ART27.13 following positive Phase 2 data

* Company finalizing protocol for ART26.12 multiple ascending dose study

Result Drivers

* R&D - Research and development expenses were $1.3 million for the quarter ended September 30, 2025, compared to $0.3 million for the same period in 2024, during which $1.3 million of UK tax credits were received

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$3.10

Income mln

Analyst Coverage

* The one available analyst rating on the shares is "hold"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)